1 June 2022: In the final discussion of the World Health Assembly, Member States noted with appreciation new Global Health Sector Strategies for HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. WHO is looking forward to implementing the core elements of these strategies with all Member States and was heartened to see their broad support for ending these diseases.
The global health sector strategies aim to reignite momentum in the responses to these diseases that had been eroded by disruptions to services during the COVID-19 pandemic. They set out to simultaneously strengthen responses to specific diseases while increasingly integrating them into broader health frameworks and taking opportunities, where feasible, to increase impact by addressing aspects of the diseases jointly.
The strategies call for a more precise focus to reach the people who are most affected and most at risk for each disease, and to address inequities. They promote synergies under a universal health coverage and primary health care framework. They also outline actions to identify and manage future outbreaks of HIV, viral hepatitis and sexually transmitted infections, as well as other emerging health threats, as these arise.
HIV, viral hepatitis and sexually transmitted infections present ongoing and persistent public health challenges and combined, are responsible for 2.3 million deaths and are associated with 1.2 million cases of cancer each year.
More information on the global health sector strategies
Download final full document (PDF, 1.85 MB)
Available in following languages:
Français | Español | عربي | 中文 | Русский
More about the global health sector strategies development process
Health topics
Sexually Transmitted Infections (STIs)
SEE ALSO:
- Health Policy Watch: WHA approves strategy on HIV, hepatitis B and STIs – after prolonged debate over sexual health terminology
- POZ: Disputes over the new Global Strategy to combat HIV, hepatitis and STIs
Source : World Health Organization
Related HIV and Co-Infections News
-
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences
-
EurekAlert!: Between 2.4 and 4.1 million people estimated to be living with chronic hepatitis B infection in Europe
-
AVAC: Abrupt shutdown of US global health supply chain raises risks for HIV, TB and malaria programs
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.